Always good to hear from you Japes. I think that the intention...

First 39 Last

Share
Profile

Follow
Hoyland

4,015 Posts.

127

14/08/15

12:50

Post #: 15808109
Share

Originally posted by Japes ↑

Hi Hoy,
Everybody & his dog are trying to fix wet AMD, so that won't generate much new investor interest , IMO.
Wet is a popular target because the eye is a fairly protected organ from mistakes escaping back into the rest of the body. Its presently treated with 1-2 monthly injections to stop bleeding in the subretinal space.
I'm not clear what Benitec are saying about Dry AMD, the much more common disease - fore-runner of wet AMD. Dry is a huge market in the aged population, but neither are life threatening. If they are the only ones chasing Dry, I think they'd need to spell it out louder & clearer. They do list 2 targets.
What are the goals? Just halt it from getting worse or restore back to normal? Wet AMD causes quite a bit of physical damage to the base layer of the macular by buckling it out of shape.
Its all a large market, but they'd need a more catchy song to woo US investors.
I'm pretty sure they could do the clinical trials anywhere in the US, UK, Europe, 'ere or Asia. All blindness charities & governments are aware of the risk to over 50's.
I think we inherited BLT's technology from Tacere. Maybe they did some safety in vitro & in vivo with mice & rats in UK. But I think its a human only disorder caused by hard to identify mutations. Benitec seem to be saying: This peculiarity seems to manifest in most AMD disorders, so lets knock it out in every patient, or that's how I read it, but I'm no scientist.
Bit of a bummer of a day, Cheers, Japes.

Expand

Always good to hear from you Japes. I think that the intention with AMD is to find a treatment for both Wet and Dry versions. If we can get this to work, then we will have (or have exclusivity to) patents for both the ddRNAi component and the specially designed vector. This should, therefore, have some attraction to investor capital.

BLT Price at posting: 73.0¢ Sentiment: None Disclosure: Held
1 Upvote

0 Great analysis

Reply

Top Stories

Emerald & Azure score Digger & Dealer awards

Revolutionary inverter technology leads the clean energy charge

Dale Gillham's weekly wrap: picking resilient stocks in a volatile global market

Bitcoin: Current State of Play & Where to Next | Swyftx

TNC

True North increases silver metal at QLD's Vero deposit by 20%

Week 32 Wrap: AI is clearly overhyped – but did we see ‘bubble’ burst already? Plus RBA decision; Japan’s wild week & Google ruling

TKM

Trek Metals jumps 5% as gold & REE drill run kicks off at Christmas Creek in the Kimberley

From the Floor with Federal Opposition Leader Peter Dutton at Diggers & Dealers 2024

NEU

Neuren Pharmaceuticals dips after pediatric Angelman Syndrome Phase 2 trial results fail to impress

HZR

Hazer Group reports ten days of continuous operation at graphite-manufacturing test facility

There are more pages in this discussion • 1 more message in this thread...

First 39 Last

Add BLT (ASX) to my watchlist

Always good to hear from you Japes. I think that the intention...

Top Stories

Emerald & Azure score Digger & Dealer awards

Revolutionary inverter technology leads the clean energy charge

Dale Gillham's weekly wrap: picking resilient stocks in a volatile global market

Bitcoin: Current State of Play & Where to Next | Swyftx

True North increases silver metal at QLD's Vero deposit by 20%

Week 32 Wrap: AI is clearly overhyped – but did we see ‘bubble’ burst already? Plus RBA decision; Japan’s wild week & Google ruling

Trek Metals jumps 5% as gold & REE drill run kicks off at Christmas Creek in the Kimberley

From the Floor with Federal Opposition Leader Peter Dutton at Diggers & Dealers 2024

Neuren Pharmaceuticals dips after pediatric Angelman Syndrome Phase 2 trial results fail to impress

Hazer Group reports ten days of continuous operation at graphite-manufacturing test facility

Featured News